AMSBIO Expands US Operations
News Apr 23, 2014
AMSBIO has announced the opening of a new North American headquarters with executive management facilities in Cambridge, MA for its US subsidiary - AMSBIO LLC.
Commenting on this strategic move, Alex Sim (President, AMSBIO) said “The US is the single largest market for our stem cell and regenerative medicine, glycobiology enzymes / substrates and tissue derived products. Drawing upon our in-depth expertise in extracellular matrices we are able to also provide elegant solutions for studying cell motility, migration, invasion and proliferation”.
He added “Our North American customer base has been growing strongly over recent years. From the new East Coast facility we will provide local informed service and support as well as next day delivery of a comprehensive range of enabling technology products to help improve the productivity of our US customers”.
New Class of Decoy Molecules that Prevent the Onset of PainNews
Researcher report a new method of reducing pain-associated behaviors with RNA-based medicine, creating a new class of decoy molecules that prevent the onset of pain.READ MORE
New Class of Drugs for the Treatment of Advanced Lung DiseaseNews
Researchers have demonstrated the potential of a new class of drugs for the treatment of refractory chronic obstructive pulmonary disease, i.e. COPD.READ MORE
Heart-muscle Patches Created from Human Cells Improve Recovery from Heart AttacksNews
Large, human cardiac-muscle patches created in the lab have been tested, for the first time, on large animals in a heart attack model. This clinically relevant approach showed that the patches significantly improved recovery from heart attack injury.READ MORE